Introduction Aspirin and a potent platelet P2Y12 inhibitor, such as prasugrel or ticagrelor,
are not always sufficient to prevent thrombus formation in patients with ST-elevation MI …

Background Aspirin and platelet P2Y 12 inhibitors, such as ticagrelor, suboptimally inhibit
microvascular thrombosis during ST-elevation myocardial infarction. Glycoprotein (GP) …

Background Glycoprotein IIb/IIIa inhibitors (GPIs) in combination with clopidogrel improve
clinical outcome in ST-elevation myocardial infarction (STEMI); however, finding a balance …

New antithrombotic medications with less effect on haemostasis are needed for the long-
term treatment of acute coronary syndromes (ACS). The platelet receptor glycoprotein VI …

Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage
has been a matter of interest since the beginning of percutaneous revascularization. After …

The efficiency of current dual antiplatelet therapy might be further improved by its
combination with a glycoprotein (GP) VI-targeting strategy without increasing bleeding. GPVI …

Improved antithrombotic therapies have remarkably enhanced the safety and efficacy of
percutaneous coronary intervention (PCI). Although rates of short-term ischemic …

2 difference was apparent only at 1 h after administration, with comparable platelet inhibition
in the two groups at 2, 4 and 8 h. However, clinical trials in patients with STEMI undergoing …

Introduction Patients with type-2 diabetes are twice as likely to suffer from acute myocardial
infarction (AMI) and have a higher incidence of recurrent events than their non-diabetic …

In the acute management of ST-elevation myocardial infarction (STEMI), glycoprotein IIb/IIIa
inhibitors (GPIs) bolus not followed by intravenous infusion is potentially advantageous …